Introduction of GI Wellness Committee to reduce GI fellow burnout and improve wellness.

Gastroenterology (GI) fellowship is an arduous process which predisposes fellows to fatigue and burnout. Our baseline survey showed a large number of our fellows to be in danger of burnout. Aims for Improvement To improve the overall wellness of GI fellows, identify stressors and reduce incidence of burnout. The goal for the first 6 months of operation is to demonstrate improvement in Mini ReZ survey scores by 25% at starting from Sept 1st, 2020

Improving the Patient Colonoscopy Prep Experience

AIM: To improve patient prep compliance, prep quality, and an overall better experience by designing a prep specific website that will address the most common prep questions and concerns Once launched, the website address will be placed on printed colonoscopy prep instructions and stated on the after hours GI clinic voicemail as an additional patient resourcehttps://jdc.jefferson.edu/patientsafetyposters/1049/thumbnail.jp

Metal organic framework nanosheets in polymer composite materials for gas separation

[EN] Composites incorporating two-dimensional nanostructures within polymeric matrices have potential as functional components for several technologies, including gas separation. Prospectively, employing metal-organic frameworks (MOFs) as versatile nanofillers would notably broaden the scope of functionalities. However, synthesizing MOFs in the form of freestanding nanosheets has proved challenging. We present a bottom-up synthesis strategy for dispersible copper 1,4-benzenedicarboxylate MOF lamellae of micrometre lateral dimensions and nanometre thickness. Incorporating MOF nanosheets into polymer matrices endows the resultant composites with outstanding CO2 separation performance from CO2/CH4 gas mixtures, together with an unusual and highly desired increase in the separation selectivity with pressure. As revealed by tomographic focused ion beam scanning electron microscopy, the unique separation behaviour stems from a superior occupation of the membrane cross-section by the MOF nanosheets as compared with isotropic crystals, which improves the efficiency of molecular discrimination and eliminates unselective permeation pathways. This approach opens the door to ultrathin MOF-polymer composites for various applications.The research leading to these results has received funding (J.G., B.S.) from the European Research Council under the European Union’s Seventh Framework Programme (FP/2007-2013)/ERC Grant Agreement no. 335746, CrystEng-MOF-MMM. T.R. is grateful to TUDelft for funding. G.P. acknowledges the A. von Humboldt Foundation for a research grant. A.C., I.L. and F.X.L.i.X. thank Consolider-Ingenio 2010 (project MULTICAT) and the ‘Severo Ochoa’ programme for support. I.L. also thanks CSIC for a JAE doctoral grant.Ródenas Torralba, T.; Luz Mínguez, I.; Prieto González, G.; Seoane, B.; Miro, H.; Corma Canós, A.; Kapteijn, F.... (2015). Metal organic framework nanosheets in polymer composite materials for gas separation. Nature Materials. 14(1):48-55. https://doi.org/10.1038/nmat4113S4855141Stankovich, S. et al. Graphene-based composite materials. Nature 442, 282–286 (2006).Wang, Q. H., Kalantar-Zadeh, K., Kis, A., Coleman, J. N. & Strano, M. S. Electronics and optoelectronics of two-dimensional transition metal dichalcogenides. Nature Nanotech. 7, 699–712 (2012).Choi, S. et al. Layered silicates by swelling of AMH-3 and nanocomposite membranes. Angew. Chem. Int. Ed. 47, 552–555 (2008).Varoon, K. et al. Dispersible exfoliated zeolite nanosheets and their application as a selective membrane. Science 334, 72–75 (2011).Corma, A., Fornes, V., Pergher, S. B., Maesen, Th. L. M. & Buglass, J. G. Delaminated zeolite precursors as selective acidic catalysts. Nature 396, 353–356 (1998).Hernandez, Y. et al. High-yield production of graphene by liquid-phase exfoliation of graphite. Nature Nanotech. 3, 563–568 (2008).Li, P-Z., Maeda, Y. & Xu, Q. Top-down fabrication of crystalline metal-organic framework nanosheets. Chem. Commun. 47, 8436–8438 (2011).Choi, M. et al. Stable single-unit-cell nanosheets of zeolite MFI as active and long-lived catalysts. Nature 461, 246–249 (2009).Hu, G., Wang, N., O’Hare, D. & Davis, J. One-step synthesis and AFM imaging of hydrophobic LDH monolayers. Chem. Commun. 287–289 (2006).Yamamoto, K., Sakata, Y., Nohara, Y., Takahashi, Y. & Tatsumi, T. Organic-inorganic hybrid zeolites containing organic frameworks. Science 300, 470–472 (2003).Yaghi, O. M. et al. Reticular synthesis and the design of new materials. Nature 423, 705–714 (2003).Férey, G. Hybrid porous solids: Past, present, future. Chem. Soc. Rev. 37, 191–214 (2008).Gücüyener, C., Bergh, J., Gascon, J. & Kapteijn, F. Ethane/ethene separation turned on its head: Selective ethane adsorption on the metal-organic framework ZIF-7 through a gate-opening mechanism. J. Am. Chem. Soc. 132, 17704–17706 (2010).Deng, H. et al. Multiple functional groups of varying ratios in metal-organic frameworks. Science 12, 846–850 (2010).Khaletskaya, K. et al. Integration of porous coordination polymers and gold nanorods into core-shell mesoscopic composites toward light-induced molecular release. J. Am. Chem. Soc. 135, 10998–11005 (2013).Corma, A., Garcia, H. & Llabrés i Xamena, F. X. Engineering metal organic frameworks for heterogeneous catalysis. Chem. Rev. 110, 4606–4655 (2010).Mueller, U. et al. Metal-organic frameworks-prospective industrial applications. J. Mater. Chem. 16, 626–636 (2006).Gascon, J. & Kapteijn, F. Metal-organic framework membranes-high potential, bright future? Angew. Chem. Int. Ed. 49, 1530–1532 (2010).Li, Y. S. et al. Controllable synthesis of metal-organic frameworks: From MOF nanorods to oriented MOF membranes. Adv. Mater. 22, 3322–3326 (2010).Gascon, J. et al. Practical approach to zeolitic membranes and coatings: State of the art, opportunities, barriers, and future perspectives. Chem. Mater. 24, 2829–2844 (2012).Bae, T-H. et al. A high-performance gas-separation membrane containing submicrometer-sized metal-organic framework crystals. Angew. Chem. Int. Ed. 49, 9863–9866 (2010).Zornoza, B. et al. Functionalized flexible MOFs as fillers in mixed matrix membranes for highly selective separation of CO2 from CH4 at elevated pressures. Chem. Commun. 47, 9522–9524 (2011).Zornoza, B., Tellez, C., Coronas, J., Gascon, J. & Kapteijn, F. Metal organic frameworks based mixed matrix membranes: An increasingly important field of research with a large application potential. Microp. Mesop. Mater. 166, 67–78 (2013).Zhang, C., Dai, Y., Johnson, J. R., Karvan, O. & Koros, W. High performance ZIF-8/6FDA-DAM mixed matrix membrane for propylene/propane separations. J. Mem. Sci. 389, 34–42 (2012).Li, T., Pan, Y., Peinemann, K-V. & Lai, Z. Carbon dioxide selective mixed matrix composite membrane containing ZIF-7 nano-fillers. J. Mem. Sci. 425–426, 235–242 (2013).Makiura, R. et al. Surface nano-architecture of a metal-organic framework. Nature Mater. 9, 565–571 (2010).Mori, W. et al. Synthesis of new adsorbent copper(II) terephthalate. Chem. Lett. 26, 1219–1220 (1997).Xin, Z., Bai, J., Shen, Y. & Pan, Y. Hierarchically micro- and mesoporous coordination polymer nanostructures with high adsorption performance. Cryst. Growth Des. 10, 2451–2454 (2010).Adams, R., Carson, C., Ward, J., Tannenbaum, R. & Koros, W. Metal organic framework mixed matrix membranes for gas separations. Micropor. Mesopor. Mater. 131, 13–20 (2010).Carson, C. G. et al. Synthesis and structure characterization of copper terephthalate metal-organic framework. Eur. J. Inorg. Chem. 2009, 2338–2343 (2009).Ameloot, R. et al. Interfacial synthesis of hollow metal-organic framework capsules demonstrating selective permeability. Nature Chem. 3, 382–387 (2011).Chen, Z. et al. Microporous metal-organic framework with immobilized -OH functional groups within the pore surfaces for selective gas sorption. Eur. J. Inorg. Chem. 2010, 3745–3749 (2010).Karra, J. R. & Walton, K. S. Molecular simulations and experimental studies of CO2, CO, and N2 adsorption in metal-organic frameworks. J. Phys. Chem. C 114, 15735–15740 (2010).Liu, J., Thallapally, P. K., McGrail, B. P., Brown, D. R. & Liu, J. Progress in adsorption-based CO2 capture by metal-organic frameworks. Chem. Soc. Rev. 41, 2308–2322 (2012).Seki, K., Takamizawa, S. & Mori, W. Characterization of microporous copper(II) dicarboxylates (fumarate, terephthalate, and trans-1,4-cyclohexanedicarboxylate) by gas adsorption. Chem. Lett. 30, 122–123 (2001).Carson, C. G. et al. Structure solution from powder diffraction of copper 1,4-benzenedicarboxylate. Eur. J. Inorg. Chem. 2014, 2140–2145 (2014).Corma, A., Diaz, U., Domine, M. E. & Fornes, V. AlITQ-6 and TiITQ-6: Synthesis, characterization, and catalytic activity. Angew. Chem. Int. Ed. 39, 1499–1501 (2000).Corma, A., Fornes, V. & Diaz, U. ITQ-18 a new delaminated stable zeolite. Chem. Commun. 2642–2643 (2001).Rouquerol, F., Rouquerol, J. & Sing, K. Adsorption by Powders and Porous Solids (Academic, 1999).Dubinin, M. M. The potential theory of adsorption of gases and vapors for adsorbents with energetically nonuniform surfaces. Chem. Rev. 60, 235–241 (1960).Uchic, M. D., Holzer, L., Inkson, B. J., Principe, E. L. & Munroe, P. Three-dimensional microstructural characterization using focused ion beam tomography. Mater. Res. Soc. Bull. 32, 408–416 (2007).Rodenas, T. et al. Visualizing MOF mixed matrix membranes at the nanoscale: Towards structure-performance relationships in CO2/CH4 separation over NH2-MIL-53(Al)@PI. Adv. Funct. Mater. 24, 249–256 (2013).Wang, X. et al. Unusual rheological behaviour of liquid polybutadiene rubber/clay nanocomposite gels: The role of polymer-clay interaction, clay exfoliation, and clay orientation and disorientation. Macromology 39, 6653–6660 (2006).Yang, Y. et al. Progress in carbon dioxide separation and capture: A review. J. Environ. Sci. 20, 14–27 (2008).Yeo, Z. Y., Chew, T. L., Zhu, P. W., Mohamed, A. R. & Chai, S-P. Conventional processes and membrane technology for carbon dioxide removal from natural gas: A review. J. Nature Gas Chem. 21, 282–298 (2012).McKeown, N. B. & Budd, P. M. Polymers of intrinsic microporosity (PIMs): Organic materials for membrane separations, heterogeneous catalysis and hydrogen storage. Chem. Soc. Rev. 35, 675–683 (2006).Vinh-Thang, H. & Kaliaguine, S. Predictive models for mixed-matrix membrane performance: A review. Chem. Rev. 113, 4980–5028 (2013)

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial

Aims  The third Universal Definition of Myocardial Infarction (MI) Task Force classified MIs into five types: Type 1, spontaneous; Type 2, related to oxygen supply/demand imbalance; Type 3, fatal without ascertainment of cardiac biomarkers; Type 4, related to percutaneous coronary intervention; and Type 5, related to coronary artery bypass surgery. Low-density lipoprotein cholesterol (LDL-C) reduction with statins and proprotein convertase subtilisin–kexin Type 9 (PCSK9) inhibitors reduces risk of MI, but less is known about effects on types of MI. ODYSSEY OUTCOMES compared the PCSK9 inhibitor alirocumab with placebo in 18 924 patients with recent acute coronary syndrome (ACS) and elevated LDL-C (≥1.8 mmol/L) despite intensive statin therapy. In a pre-specified analysis, we assessed the effects of alirocumab on types of MI. Methods and results  Median follow-up was 2.8 years. Myocardial infarction types were prospectively adjudicated and classified. Of 1860 total MIs, 1223 (65.8%) were adjudicated as Type 1, 386 (20.8%) as Type 2, and 244 (13.1%) as Type 4. Few events were Type 3 (n = 2) or Type 5 (n = 5). Alirocumab reduced first MIs [hazard ratio (HR) 0.85, 95% confidence interval (CI) 0.77–0.95; P = 0.003], with reductions in both Type 1 (HR 0.87, 95% CI 0.77–0.99; P = 0.032) and Type 2 (0.77, 0.61–0.97; P = 0.025), but not Type 4 MI. Conclusion  After ACS, alirocumab added to intensive statin therapy favourably impacted on Type 1 and 2 MIs. The data indicate for the first time that a lipid-lowering therapy can attenuate the risk of Type 2 MI. Low-density lipoprotein cholesterol reduction below levels achievable with statins is an effective preventive strategy for both MI types.For complete list of authors see http://dx.doi.org/10.1093/eurheartj/ehz299</p

Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021

BACKGROUND Regular, detailed reporting on population health by underlying cause of death is fundamental for public health decision making. Cause-specific estimates of mortality and the subsequent effects on life expectancy worldwide are valuable metrics to gauge progress in reducing mortality rates. These estimates are particularly important following large-scale mortality spikes, such as the COVID-19 pandemic. When systematically analysed, mortality rates and life expectancy allow comparisons of the consequences of causes of death globally and over time, providing a nuanced understanding of the effect of these causes on global populations. METHODS The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 cause-of-death analysis estimated mortality and years of life lost (YLLs) from 288 causes of death by age-sex-location-year in 204 countries and territories and 811 subnational locations for each year from 1990 until 2021. The analysis used 56 604 data sources, including data from vital registration and verbal autopsy as well as surveys, censuses, surveillance systems, and cancer registries, among others. As with previous GBD rounds, cause-specific death rates for most causes were estimated using the Cause of Death Ensemble model-a modelling tool developed for GBD to assess the out-of-sample predictive validity of different statistical models and covariate permutations and combine those results to produce cause-specific mortality estimates-with alternative strategies adapted to model causes with insufficient data, substantial changes in reporting over the study period, or unusual epidemiology. YLLs were computed as the product of the number of deaths for each cause-age-sex-location-year and the standard life expectancy at each age. As part of the modelling process, uncertainty intervals (UIs) were generated using the 2·5th and 97·5th percentiles from a 1000-draw distribution for each metric. We decomposed life expectancy by cause of death, location, and year to show cause-specific effects on life expectancy from 1990 to 2021. We also used the coefficient of variation and the fraction of population affected by 90% of deaths to highlight concentrations of mortality. Findings are reported in counts and age-standardised rates. Methodological improvements for cause-of-death estimates in GBD 2021 include the expansion of under-5-years age group to include four new age groups, enhanced methods to account for stochastic variation of sparse data, and the inclusion of COVID-19 and other pandemic-related mortality-which includes excess mortality associated with the pandemic, excluding COVID-19, lower respiratory infections, measles, malaria, and pertussis. For this analysis, 199 new country-years of vital registration cause-of-death data, 5 country-years of surveillance data, 21 country-years of verbal autopsy data, and 94 country-years of other data types were added to those used in previous GBD rounds. FINDINGS The leading causes of age-standardised deaths globally were the same in 2019 as they were in 1990; in descending order, these were, ischaemic heart disease, stroke, chronic obstructive pulmonary disease, and lower respiratory infections. In 2021, however, COVID-19 replaced stroke as the second-leading age-standardised cause of death, with 94·0 deaths (95% UI 89·2-100·0) per 100 000 population. The COVID-19 pandemic shifted the rankings of the leading five causes, lowering stroke to the third-leading and chronic obstructive pulmonary disease to the fourth-leading position. In 2021, the highest age-standardised death rates from COVID-19 occurred in sub-Saharan Africa (271·0 deaths [250·1-290·7] per 100 000 population) and Latin America and the Caribbean (195·4 deaths [182·1-211·4] per 100 000 population). The lowest age-standardised death rates from COVID-19 were in the high-income super-region (48·1 deaths [47·4-48·8] per 100 000 population) and southeast Asia, east Asia, and Oceania (23·2 deaths [16·3-37·2] per 100 000 population). Globally, life expectancy steadily improved between 1990 and 2019 for 18 of the 22 investigated causes. Decomposition of global and regional life expectancy showed the positive effect that reductions in deaths from enteric infections, lower respiratory infections, stroke, and neonatal deaths, among others have contributed to improved survival over the study period. However, a net reduction of 1·6 years occurred in global life expectancy between 2019 and 2021, primarily due to increased death rates from COVID-19 and other pandemic-related mortality. Life expectancy was highly variable between super-regions over the study period, with southeast Asia, east Asia, and Oceania gaining 8·3 years (6·7-9·9) overall, while having the smallest reduction in life expectancy due to COVID-19 (0·4 years). The largest reduction in life expectancy due to COVID-19 occurred in Latin America and the Caribbean (3·6 years). Additionally, 53 of the 288 causes of death were highly concentrated in locations with less than 50% of the global population as of 2021, and these causes of death became progressively more concentrated since 1990, when only 44 causes showed this pattern. The concentration phenomenon is discussed heuristically with respect to enteric and lower respiratory infections, malaria, HIV/AIDS, neonatal disorders, tuberculosis, and measles. INTERPRETATION Long-standing gains in life expectancy and reductions in many of the leading causes of death have been disrupted by the COVID-19 pandemic, the adverse effects of which were spread unevenly among populations. Despite the pandemic, there has been continued progress in combatting several notable causes of death, leading to improved global life expectancy over the study period. Each of the seven GBD super-regions showed an overall improvement from 1990 and 2021, obscuring the negative effect in the years of the pandemic. Additionally, our findings regarding regional variation in causes of death driving increases in life expectancy hold clear policy utility. Analyses of shifting mortality trends reveal that several causes, once widespread globally, are now increasingly concentrated geographically. These changes in mortality concentration, alongside further investigation of changing risks, interventions, and relevant policy, present an important opportunity to deepen our understanding of mortality-reduction strategies. Examining patterns in mortality concentration might reveal areas where successful public health interventions have been implemented. Translating these successes to locations where certain causes of death remain entrenched can inform policies that work to improve life expectancy for people everywhere. FUNDING Bill & Melinda Gates Foundation

Effect of alirocumab on mortality after acute coronary syndromes. An analysis of the ODYSSEY OUTCOMES randomized clinical trial

Background: Previous trials of PCSK9 (proprotein convertase subtilisin-kexin type 9) inhibitors demonstrated reductions in major adverse cardiovascular events, but not death. We assessed the effects of alirocumab on death after index acute coronary syndrome. Methods: ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab) was a double-blind, randomized comparison of alirocumab or placebo in 18 924 patients who had an ACS 1 to 12 months previously and elevated atherogenic lipoproteins despite intensive statin therapy. Alirocumab dose was blindly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL. We examined the effects of treatment on all-cause death and its components, cardiovascular and noncardiovascular death, with log-rank testing. Joint semiparametric models tested associations between nonfatal cardiovascular events and cardiovascular or noncardiovascular death. Results: Median follow-up was 2.8 years. Death occurred in 334 (3.5%) and 392 (4.1%) patients, respectively, in the alirocumab and placebo groups (hazard ratio [HR], 0.85; 95% CI, 0.73 to 0.98; P=0.03, nominal P value). This resulted from nonsignificantly fewer cardiovascular (240 [2.5%] vs 271 [2.9%]; HR, 0.88; 95% CI, 0.74 to 1.05; P=0.15) and noncardiovascular (94 [1.0%] vs 121 [1.3%]; HR, 0.77; 95% CI, 0.59 to 1.01; P=0.06) deaths with alirocumab. In a prespecified analysis of 8242 patients eligible for ≥3 years follow-up, alirocumab reduced death (HR, 0.78; 95% CI, 0.65 to 0.94; P=0.01). Patients with nonfatal cardiovascular events were at increased risk for cardiovascular and noncardiovascular deaths (P<0.0001 for the associations). Alirocumab reduced total nonfatal cardiovascular events (P<0.001) and thereby may have attenuated the number of cardiovascular and noncardiovascular deaths. A post hoc analysis found that, compared to patients with lower LDL-C, patients with baseline LDL-C ≥100 mg/dL (2.59 mmol/L) had a greater absolute risk of death and a larger mortality benefit from alirocumab (HR, 0.71; 95% CI, 0.56 to 0.90; Pinteraction=0.007). In the alirocumab group, all-cause death declined wit h achieved LDL-C at 4 months of treatment, to a level of approximately 30 mg/dL (adjusted P=0.017 for linear trend). Conclusions: Alirocumab added to intensive statin therapy has the potential to reduce death after acute coronary syndrome, particularly if treatment is maintained for ≥3 years, if baseline LDL-C is ≥100 mg/dL, or if achieved LDL-C is low. Clinical Trial Registration: URL: https://www.clinicaltrials.gov. Unique identifier: NCT01663402

Reducing the environmental impact of surgery on a global scale: systematic review and co-prioritization with healthcare workers in 132 countries

Abstract Background Healthcare cannot achieve net-zero carbon without addressing operating theatres. The aim of this study was to prioritize feasible interventions to reduce the environmental impact of operating theatres. Methods This study adopted a four-phase Delphi consensus co-prioritization methodology. In phase 1, a systematic review of published interventions and global consultation of perioperative healthcare professionals were used to longlist interventions. In phase 2, iterative thematic analysis consolidated comparable interventions into a shortlist. In phase 3, the shortlist was co-prioritized based on patient and clinician views on acceptability, feasibility, and safety. In phase 4, ranked lists of interventions were presented by their relevance to high-income countries and low–middle-income countries. Results In phase 1, 43 interventions were identified, which had low uptake in practice according to 3042 professionals globally. In phase 2, a shortlist of 15 intervention domains was generated. In phase 3, interventions were deemed acceptable for more than 90 per cent of patients except for reducing general anaesthesia (84 per cent) and re-sterilization of ‘single-use’ consumables (86 per cent). In phase 4, the top three shortlisted interventions for high-income countries were: introducing recycling; reducing use of anaesthetic gases; and appropriate clinical waste processing. In phase 4, the top three shortlisted interventions for low–middle-income countries were: introducing reusable surgical devices; reducing use of consumables; and reducing the use of general anaesthesia. Conclusion This is a step toward environmentally sustainable operating environments with actionable interventions applicable to both high– and low–middle–income countries

Mortality from gastrointestinal congenital anomalies at 264 hospitals in 74 low-income, middle-income, and high-income countries: a multicentre, international, prospective cohort study

Summary Background Congenital anomalies are the fifth leading cause of mortality in children younger than 5 years globally. Many gastrointestinal congenital anomalies are fatal without timely access to neonatal surgical care, but few studies have been done on these conditions in low-income and middle-income countries (LMICs). We compared outcomes of the seven most common gastrointestinal congenital anomalies in low-income, middle-income, and high-income countries globally, and identified factors associated with mortality. Methods We did a multicentre, international prospective cohort study of patients younger than 16 years, presenting to hospital for the first time with oesophageal atresia, congenital diaphragmatic hernia, intestinal atresia, gastroschisis, exomphalos, anorectal malformation, and Hirschsprung’s disease. Recruitment was of consecutive patients for a minimum of 1 month between October, 2018, and April, 2019. We collected data on patient demographics, clinical status, interventions, and outcomes using the REDCap platform. Patients were followed up for 30 days after primary intervention, or 30 days after admission if they did not receive an intervention. The primary outcome was all-cause, in-hospital mortality for all conditions combined and each condition individually, stratified by country income status. We did a complete case analysis. Findings We included 3849 patients with 3975 study conditions (560 with oesophageal atresia, 448 with congenital diaphragmatic hernia, 681 with intestinal atresia, 453 with gastroschisis, 325 with exomphalos, 991 with anorectal malformation, and 517 with Hirschsprung’s disease) from 264 hospitals (89 in high-income countries, 166 in middleincome countries, and nine in low-income countries) in 74 countries. Of the 3849 patients, 2231 (58·0%) were male. Median gestational age at birth was 38 weeks (IQR 36–39) and median bodyweight at presentation was 2·8 kg (2·3–3·3). Mortality among all patients was 37 (39·8%) of 93 in low-income countries, 583 (20·4%) of 2860 in middle-income countries, and 50 (5·6%) of 896 in high-income countries (p<0·0001 between all country income groups). Gastroschisis had the greatest difference in mortality between country income strata (nine [90·0%] of ten in lowincome countries, 97 [31·9%] of 304 in middle-income countries, and two [1·4%] of 139 in high-income countries; p≤0·0001 between all country income groups). Factors significantly associated with higher mortality for all patients combined included country income status (low-income vs high-income countries, risk ratio 2·78 [95% CI 1·88–4·11], p<0·0001; middle-income vs high-income countries, 2·11 [1·59–2·79], p<0·0001), sepsis at presentation (1·20 [1·04–1·40], p=0·016), higher American Society of Anesthesiologists (ASA) score at primary intervention (ASA 4–5 vs ASA 1–2, 1·82 [1·40–2·35], p<0·0001; ASA 3 vs ASA 1–2, 1·58, [1·30–1·92], p<0·0001]), surgical safety checklist not used (1·39 [1·02–1·90], p=0·035), and ventilation or parenteral nutrition unavailable when needed (ventilation 1·96, [1·41–2·71], p=0·0001; parenteral nutrition 1·35, [1·05–1·74], p=0·018). Administration of parenteral nutrition (0·61, [0·47–0·79], p=0·0002) and use of a peripherally inserted central catheter (0·65 [0·50–0·86], p=0·0024) or percutaneous central line (0·69 [0·48–1·00], p=0·049) were associated with lower mortality. Interpretation Unacceptable differences in mortality exist for gastrointestinal congenital anomalies between lowincome, middle-income, and high-income countries. Improving access to quality neonatal surgical care in LMICs will be vital to achieve Sustainable Development Goal 3.2 of ending preventable deaths in neonates and children younger than 5 years by 2030

Inhibition equivalency factors for microcystin variants in recombinant and wild-type protein phosphatase 1 and 2A assays

Altres ajuts: ICREA AcademiaIn this work, protein phosphatase inhibition assays (PPIAs) have been used to evaluate the performance of recombinant PP1 and recombinant and wild-type PP2As. The enzymes have been compared using microcystins-LR (MC-LR) as a model cyanotoxin. Whereas PP2A Rec provides a limit of detection (LOD) of 3.1 μg/L, PP1 Rec and PP2A Wild provide LODs of 0.6 and 0.5 μg/L, respectively, lower than the guideline value proposed by the World Health Organization (1 μg/L). The inhibitory potencies of seven MC variants (-LR, -RR, -dmLR, -YR, -LY, -LW and -LF) have been evaluated, resulting on 50 % inhibition coefficient (IC 50 ) values ranging from 1.4 to 359.3 μg/L depending on the MC variant and the PP. The PPIAs have been applied to the determination of MC equivalent contents in a natural cyanobacterial bloom and an artificially contaminated sample, with multi-MC profiles. The inhibition equivalency factors (IEFs) have been applied to the individual MC quantifications determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, and the estimated MC-LR equivalent content has been compared to PPIA results. PPIAs have demonstrated to be applicable as MC screening tools for environmental applications and to protect human and animal health